Apellis
Edit

Apellis

http://apellis.com/
Last activity: 08.04.2025
Active
Categories: DevelopmentLearnMedtechScienceWebsite
Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
Followers
1.23K
Website visits
46.5K /mo.
Mentions
48
Location: United States, Massachusetts, Waltham
Employees: 201-500
Total raised: $140.1M
Founded date: 2009

Investors 10

Funding Rounds 3

DateSeriesAmountInvestors
10.08.2017Series E$60M-
12.02.2016Series D$47.1M-
02.12.2014-$33M-

Mentions in press and media 48

DateTitleDescription
08.04.2025Merida Biosciences: $121 Million Raised For Creating Therapeutics For Multiple Autoimmune And Allergic DiseasesMerida Biosciences, a biotechnology company advancing a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, launched today w...
20.02.2025EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGNEMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN Thu, Feb 20, 2025 08:00 CET Report this content Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has ...
29.01.2025Prevent Blindness Declares February as Age-related Macular Degeneration and Low Vision Awareness Month to Educate Public on the Eye Disease and Available Support ProgramsFebruary declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness to educate public on one of the leading causes of vision loss. Prevent Blindness provides a wealth of free educational resources...
26.11.2024Prevent Blindness Declares Fourth Annual Geographic Atrophy Awareness Week as Dec. 2-8, 2024Prevent Blindness provides free educational resources on geographic atrophy, a form of dry age-related macular degeneration, including fact sheets, a dedicated webpage, expert videos, and more CHICAGO, Nov. 26, 2024 /PRNewswire-PRWeb/ -- Pr...
29.10.2024AbbVie’s Bold Move: Acquiring Aliada Therapeutics for CNS BreakthroughsIn a strategic maneuver that echoes the age-old adage, "the early bird catches the worm," AbbVie has set its sights on the burgeoning field of central nervous system (CNS) therapeutics. The Chicago-based pharmaceutical giant annou...
26.10.2024Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGNPivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN Sat, Oct 26, 2024 20:00 CET Report this content Statistically significant 68% (p
24.10.2024Sobi Q3 2024 report: Strong growth and significant pipeline momentumSobi Q3 2024 report: Strong growth and significant pipeline momentum Thu, Oct 24, 2024 08:00 CET Report this content Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024 Third Quarter 2024 • Total...
08.08.2024Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGNSobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN Thu, Aug 08, 2024 13:00 CET Report this content Met the primary endpoint, achieving statistically significant 68% (p
10.06.2024Sobi to present new data across its haematology portfolio at the 2024 EHA congressSobi to present new data across its haematology portfolio at the 2024 EHA congress Mon, Jun 10, 2024 12:15 CET Report this content Sobi® will present data at the EHA (European Haematology Association) hybrid congress, taking place in Madrid...
24.05.2024Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congressPositive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress Fri, May 24, 2024 16:05 CET Report this content Rapid reduction in disease activity seen at 12 weeks sustained at one year 55% of patients sho...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In